|
Market Report
|
Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth
Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.
|
|
Read more...
|
|
|
Market Report
|
Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017
Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.
|
|
Read more...
|
|
|
Market Report
|
Cancer Overview - Lung, Brain, Head and Neck, Thyroid
In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.
|
|
Read more...
|
|
|
Market Report
|
Antihypertensives: Key patent expiries prevent market growth
Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
|
Market Report
|
Asthma/COPD - Little long-term future for long-acting single-agent inhalers?
The respiratory market will continue to grow with the same rate over the next few years, with a slight dip between 2012 and 2015 due to the patent expiries of leading products. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.
|
|
Read more...
|
|
|
Market Report
|
Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition
Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.
|
|
Read more...
|
|
|
Market Report
|
Antihormonal Therapy Cancer Brands - Careful lifecycle management needed to preserve brand
Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.
|
|
Read more...
|
|
|
Market Report
|
Insomnia - Orexin and serotonin receptor modulators to innovate market
After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.
|
|
Read more...
|
|
|
Market Report
|
Commercial Insight: HIV - The battle for market share is getting fiercer
In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 19 - 27 of 238 |
Farmavita.Net Journal 
